Securities law
Shareholders of Zivo Bioscience, Inc. gathered at the annual meeting on June 9, 2025, where they voted to approve the election of two Class III directors, the reappointment of BDO USA, P.C. as the company's independent registered public accounting firm, and the compensation of the company'
Biotechnology
SyntecBio inc has emerged as a standout opportunity for investors seeking high-growth potential in the biopharma sector, which continues to grow at an impressive 7.4% annually. Leveraging cutting-edge innovation and a robust research pipeline, SyntecBio positions itself at the forefront of next-generation therapeutics. Founded in 2016, the company focuses
Biotechnology
The company, PURSUANT TO THE AUTHORITY GRANTED at the General Meeting of the Company held on 27 February 2025, has made a market purchase of its own shares. The company has purchased a total of 50,000 ordinary shares of 25p each, which will be cancelled. This purchase brings the
Biotechnology
A notification has been made by Frostrow Capital LLP on behalf of the company, stating that it has made a market purchase of its own shares. The company had been granted authority at its General Meeting held on 27 February 2025 to make these purchases, with a maximum aggregate total
Biotechnology
The Biotech Growth Trust PLC has disclosed that it has acquired a total of 155,562 of its own Ordinary shares as part of its authority to make market purchases of its shares up to a maximum of 4,255,299. This move is aimed at reducing the Company'
Biotechnology industries
Kronos Bio Inc, a biotechnology company listed on the Nasdaq under KRON, has entered into a definitive merger agreement to be acquired by Concentra Biosciences LLC for $0.57 in cash per share. The acquisition also includes contingent value rights (CVRs) that entitle shareholders to a portion of future proceeds
Biotechnology
Rossari Global DMCC has established a step-down wholly owned subsidiary, Rossari Biotech Trading FZE, with a primary focus on trading and manufacturing activities, including the distribution and sales of chemicals and consumer products for export markets. This move marks an expansion of Rossari Biotech's operations, leveraging its position
Biotechnology industries
Qualigen Therapeutics, a Delaware-based biotechnology company, has made significant changes to its leadership structure with the appointment of Braeden Lichti as an independent member of the Board of Directors, effective October 8, 2024. Lichti is the founder and CEO of BWL Investments Ltd. and NorthStrive Companies, Inc., and has a
Biotechnology
Trinity Biotech plc, a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, announced its Q2 2024 financial results today. The company reported strong revenue and profitability improvements, driven by the TrinScreen HIV business. The company's existing business segments, including TrinScreen HIV
Biotechnology
Trinity Biotech plc, a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, will report its financial results for the second quarter 2024 on Wednesday, August 14, 2024. This announcement comes as the company continues to expand its product offerings, including wearable biosensors, and enters the wearable
Biotechnology industries
Oxford Biomedica has seen continued strong momentum in 2024, with revenues for the first half expected to be approximately £50 million. The company reiterates revenue guidance for the full year within the £126 million to £134 million range, driven by strong demand for its cell and gene therapy contract development
Biotechnology industries
Trinity Biotech, a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, has announced preliminary second quarter 2024 revenues of $15.5-$16.0 million, reflecting double-digit percentage year-over-year growth. The company has also entered into a distribution agreement with MedScience, a leading distributor in the UK,
